Tissue Regenix continues US progress
TISSUE Regenix Group saw its losses increase last year but it is confident of major progress in the key US market.
The York-based regenerative medical devices company, saw operating losses widen to £6.6m from £4.4m in the year to January 31 which it said was anticipated as it accelerated investment in its development programme and pre-clinical and clinical trials.
It said its cash postion remained strong at the year end with a balance of £18.5m compared to £24.2m in 2013.
Chief executive Antony Odell, ... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...


